A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Study drug includes all investigational agents (including placebo, if applicable) administered during the course of the study.

Time frame: Baseline through Week 48

Population: The FA set included all enrolled subjects who received at least 1 dose of study drug in this study (VX06-950-107 \[NCT00535847\]).

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Time frame: 24 weeks after the completion of treatment (up to Week 72)

Population: The FA set included all enrolled subjects who received at least 1 dose of study drug in this study (VX06-950-107 \[NCT00535847\]).

Cross tabulation of number of subjects with eRVR/SVR status in present study was presented with respect to prior response status of subjects in parent studies. eRVR=undetectable HCV RNA at Week 4 and Week 12, SVR=undetectable HCV RNA at end of treatment (EOT) and at 24 weeks after last dose of study treatment without any confirmed detectable HCV RNA in between. Prior response=subjects were categorized into following categories based on their viral response in the parent study: Null Response (less than \[\<\] 1-log10 decrease in HCV RNA at Week 4 or \<2-log10 decrease in HCV RNA at Week 12), Partial Response (greater than \[\>\] 2-log10 decrease in HCV RNA at Week 12, but detectable HCV RNA at Week 24), Viral Breakthrough (detectable HCV RNA during treatment after achieving undetectable HCV RNA), Relapse (undetectable HCV RNA at EOT but detectable HCV RNA during viral follow-up). Plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay; lower limit of detection=10 IU/mL.

Time frame: Baseline up to Week 72

Population: The FA set included subjects who received at least 1 dose of study drug in this study (VX06-950-107 \[NCT00535847\]). Data was presented for overall subjects based on eRVR and SVR status as per planned analysis.

Prior relapsers: subjects who had undetectable HCV RNA at the end of treatment in parent study but reverted to detectable levels of HCV RNA after stopping treatment in parent study were categorized as prior relapsers. Percentage of prior relapsers with undetectable HCV RNA 24 weeks after the completion of treatment in this study were presented. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Time frame: 24 weeks after the completion of treatment (up to Week 72)

Population: Analysis population included all enrolled subjects who were prior relapsers in parent study (VX05-950-104 \[NCT00336479\], VX05-950-104EU \[NCT00372385\] or VX06-950-106 \[NCT00420784\]) and received at least 1 dose of study drug in this study (VX06-950-107 \[NCT00535847\]).

Subjects were considered to have an end of treatment response if they completed the assigned treatment regimen and had undetectable HCV RNA at end of treatment or prematurely discontinued the assigned treatment regimen and had undetectable HCV RNA at the time of discontinuation. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Time frame: End of treatment (up to Week 48)

Population: The FA set included all enrolled subjects who received at least 1 dose of study drug in this study (VX06-950-107 \[NCT00535847\]).

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of detection was 10 international units per milliliter (IU/mL).

Time frame: 48 weeks after completion of treatment (up to Week 96)

Population: Analysis population included subjects who completed assigned treatment in this study (VX06-950-107 \[NCT00535847\]).